OncoSec Pushes IL-12 Approach Forward In PD-1 Melanoma Failures
Company plans to pursue accelerated approval based on a single-arm registrational study of PD-1 failures, after reporting positive results from a Phase II study at the ASCO-SITC meeting.
You may also be interested in...
BioNTech's $150m offering, after a prior large venture capital financing, gives it the third-largest market cap for a newly public drug developer in the US. Also, Innovent raises $300m in Hong Kong offering, Heron leads US follow-ons and Five Prime restructures to save $20m annually.
Public Company Edition: An SEC complaint alleges that the company, Opko CEO Frost and co-defendants bought penny stocks, pumped up their value, then dumped shares for sizeable profits. Also, Pfizer and Retrophin float debt offerings, while Zealand sells royalties and milestone fees to raise cash.
Early data from small studies presented at the Society of Melanoma Research meeting suggest potential for safely and effectively combining PD-1 inhibitors with a range of drugs, including Amgen’s Imlygic vaccine.